Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$20.06M
Enterprise ValueAU$54.16
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelPainChek's licensing/subscription model sells enterprise access to aged-care and clinical customers, creating durable recurring revenue. Enterprise contracts, onboarding and support items foster multi-year relationships and upsell potential, improving predictability of cash flows over months.
Top-line Momentum And Margin ExpansionAccelerating revenue and a rising gross margin to ~30% indicate improving product-market fit and unit economics. Sustained top-line growth plus margin gains support longer-term operating leverage if the company scales deployments across aged-care and hospital sites.
No Debt On Balance SheetAn absence of debt lowers fixed financial obligations and interest burden, preserving operational flexibility. This structural advantage improves runway options (equity raises or partnerships) and reduces insolvency risk while management works to convert growth into positive cash flow.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow (~-6.8M) shows the business is not yet self-funding; sustained burn increases reliance on external capital. Over a multi-month horizon, this raises dilution and execution risk if revenue acceleration or funding access slows.
Negative Shareholders' EquityA shift to negative equity reflects accumulated deficits and a weakened capital cushion. Structurally, negative equity can constrain financing choices, reduce lender confidence, and signal the need for recapitalisation, making medium-term stability contingent on successful funding or rapid profit improvement.
Deep UnprofitabilityExtremely negative net and operating margins indicate current revenues are far below the cost base. Without material cost reduction or marked revenue scale-up, such structural losses will persist, undermining long-term free cash flow conversion and heightening execution and funding risk.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.10 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$20.06M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 22 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.04%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―